1.Previous
3.Next

and Bucheon. In 1998, Management re-branded Sunkyong to SK. In 1999, SK Chemicals developed third-generation (non cross resistant) platinum-complex anti-cancer agent. Also, by focusing its research and development efforts on life sciences, SK Corporation developed YKP1358, a new drug candidate for schizophrenia, in 2003. In 2002, SK Telecom successfully launched the world's first commercial CDMA 1X EV-DO technology,

1.Previous
3.Next